Compugen: In the NEWS
Compugen (CGEN) was granted a new patent for the composition of COM701 or backup antibodies for the treatment of cancer by the European Patent Office (EPO).
The EPO Patent No. 3295951 titled, “Anti-PVRIG Antibodies and Methods of Use”, covers the composition of matter for COM701 and backup antibodies including any anti-PVRIG antibody having the binding fragments of COM701 or backup antibodies for the treatment of cancer.
The patent is expected to expire in Europe no earlier than February 2036.
This news adds to other good news we expect to hear from Compugen.